Project Grant K08HL171833
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$159K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $834,531 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), a risk factor for atherosclerotic cardiovascular disease. The research aims to investigate vascular...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $104,933 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant supports research to determine the role of age-related clonal hematopoiesis of indeterminate potential (CHIP), an inflammatory biomarker, in cardiorespiratory fitness (CRF) and cardiometabolic responses to chronic exercise interventions. The project aims to evaluate whether CHIP is associated with baseline CRF and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $786,060 to Vanderbilt University Medical Center to study how hypertension induces "trained immunity" in myeloid cells, potentially contributing to chronic inflammation and increased risk of atherosclerotic cardiovascular disease. The research aims to determine how hypertension rewires the epigenome of myeloid progenitors, leading...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Vanderbilt University Medical Center (VUMC) a $150,000 Project Grant under CFDA 93.847, the Diabetes, Digestive, and Kidney Diseases Extramural Research program. The grant, which runs from Sep 1, 2023 to Aug 31, 2024, will fund a study to identify factors that contribute to clonal expansion and disease progression in clonal hematopoiesis of indeterminate potential (CHIP). The research aims to dissect the...
This Project Grant award of $2,653,601 from the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) supports research to identify genetic, environmental, and molecular factors that influence the rate of clonal hematopoiesis (CH) expansion and associated health outcomes across the human lifespan. The key objectives are to: 1) apply a computational method to estimate CH expansion rates in over 1.6 million individuals to identify genetic factors conferring...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $165,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Dana-Farber Cancer Institute (DFCI) in Boston, MA. The grant will fund a 5-year research project led by Dr. Lachelle D. Weeks to define the relationship between clonal hematopoiesis (CH) and inflammatory disease outcomes. The project aims to: 1) Determine the association between CH and rheumatologic diseases, 2) Identify CH genotypes...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $2,488,671.00 from September 1, 2024 through June 30, 2029 to Washington University in St. Louis to conduct research on the impact of inherited and modifiable risk factors on clonal hematopoiesis (CH) and its association with age-related diseases like cardiovascular disease and Alzheimer's disease. The study will leverage longitudinal data from large biobanks and cohorts to characterize...